In summary, hsBCL9z96 demonstrates robust antitumor activity in colon cancer, melanoma and breast cancer models with improved feature of cell permeability, suggesting hsBCL9z96 is a good research tool of pharmacological inhibition of BCL9/β-catenin driven Wnt transcriptional activity. This evidence concerns the gene BCL9 and breast cancer.